Momelotinib
Cat. No.：YN340067
CAS No. ：1056634-68-4
| 产品名称: | Momelotinib |
| CAS No.: | 1056634-68-4 |
| Chemical Name: | N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide |
| Synonyms: | CYT387 |
| 分子量: | 414.46 |
| 分子式: | C₂₃H₂₂N₆O₂ |
| SMILES: | O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Momelotinib (CYT387) 是 ATP 竞争性的JAK1/JAK2抑制剂，IC50值分别为 11 nM/18 nM，是对 JAK3 选择性的 10 倍左右。 |
| IC50和靶点: | [{name:"JAK1:11 nM (IC50)"},{name: "JAK2:18 nM (IC50)"},{name: "JAK3:155 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Tyner, J.W., Bumm, T.G., Deininger, J., et al.CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasmsBlood115(25),5232-5240(2010)
Furqan, M., Mukhi, N., Lee, B., et al.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical applicationBiomark. Res.1(1),5(2013)
Deshpande, A., Reddy, M.M., Schade, G.O.M., et al.Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasmsLeukemia26(4),708-715(2012)
Abubaker, K., Luwor, R.B., Zhu, H., et al.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenBMC Cancer14,317(2014)
